Trust Co. of Toledo NA OH Sells 30 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Trust Co. of Toledo NA OH lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.7% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 787 shares of the medical research company’s stock after selling 30 shares during the quarter. Trust Co. of Toledo NA OH’s holdings in Thermo Fisher Scientific were worth $411,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in TMO. Moneta Group Investment Advisors LLC grew its position in shares of Thermo Fisher Scientific by 104,536.8% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock worth $4,601,150,000 after buying an additional 8,347,260 shares in the last quarter. Providence Capital Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 61,754.7% during the 1st quarter. Providence Capital Advisors LLC now owns 5,842,175 shares of the medical research company’s stock worth $10,136,000 after purchasing an additional 5,832,730 shares during the last quarter. Norges Bank purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $3,105,677,000. Polen Capital Management LLC purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $1,208,055,000. Finally, Morgan Stanley lifted its stake in shares of Thermo Fisher Scientific by 17.7% during the 4th quarter. Morgan Stanley now owns 11,730,063 shares of the medical research company’s stock worth $6,459,629,000 after purchasing an additional 1,764,312 shares during the last quarter. Institutional investors own 87.06% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $549.00, for a total transaction of $5,490,000.00. Following the completion of the transaction, the chief executive officer now directly owns 141,330 shares of the company’s stock, valued at approximately $77,590,170. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $549.00, for a total value of $5,490,000.00. Following the sale, the chief executive officer now owns 141,330 shares in the company, valued at approximately $77,590,170. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Stephen Williamson sold 14,100 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $550.00, for a total value of $7,755,000.00. Following the completion of the sale, the chief financial officer now owns 27,393 shares in the company, valued at approximately $15,066,150. The disclosure for this sale can be found here. In the last three months, insiders sold 28,700 shares of company stock valued at $15,799,270. Corporate insiders own 0.32% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on TMO shares. Royal Bank of Canada upped their price objective on Thermo Fisher Scientific from $662.00 to $698.00 in a research note on Thursday, July 27th. JPMorgan Chase & Co. raised their target price on Thermo Fisher Scientific from $660.00 to $670.00 in a report on Thursday, July 27th. KeyCorp dropped their price objective on Thermo Fisher Scientific from $710.00 to $640.00 in a report on Thursday, May 25th. Barclays lifted their price target on Thermo Fisher Scientific from $590.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, July 27th. Finally, Raymond James lifted their target price on Thermo Fisher Scientific from $595.00 to $630.00 and gave the company an “outperform” rating in a research report on Friday, July 28th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $631.71.

Thermo Fisher Scientific Stock Down 0.0 %

Thermo Fisher Scientific stock opened at $515.42 on Friday. The stock has a 50-day simple moving average of $540.34 and a 200-day simple moving average of $541.69. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.02 and a current ratio of 1.42. The company has a market capitalization of $198.93 billion, a P/E ratio of 35.23, a PEG ratio of 2.43 and a beta of 0.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $475.77 and a fifty-two week high of $609.85.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 26th. The medical research company reported $5.15 EPS for the quarter, missing the consensus estimate of $5.43 by ($0.28). The company had revenue of $10.69 billion for the quarter, compared to analysts’ expectations of $10.99 billion. Thermo Fisher Scientific had a net margin of 13.14% and a return on equity of 18.59%. The firm’s revenue was down 2.6% on a year-over-year basis. During the same period in the prior year, the company earned $5.51 earnings per share. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 22.37 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 13th. Stockholders of record on Friday, September 15th will be paid a dividend of $0.35 per share. This represents a $1.40 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.57%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.